Brookstone Capital Management Has $3.23 Million Holdings in United Therapeutics Corporation $UTHR

Brookstone Capital Management grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 25.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,622 shares of the biotechnology company’s stock after purchasing an additional 1,342 shares during the quarter. Brookstone Capital Management’s holdings in United Therapeutics were worth $3,227,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics in the 3rd quarter valued at $317,617,000. Invesco Ltd. raised its stake in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. AQR Capital Management LLC lifted its holdings in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the period. Balyasny Asset Management L.P. lifted its holdings in United Therapeutics by 863.9% in the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after buying an additional 136,883 shares during the period. Finally, Sofinnova Investments Inc. bought a new stake in United Therapeutics during the second quarter valued at $34,055,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This trade represents a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 361,820 shares of company stock worth $182,730,910. 10.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on UTHR shares. Wells Fargo & Company increased their price target on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Royal Bank Of Canada boosted their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $586.00.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study’s key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
• Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
• Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso’s impact on valuation); these shape investor expectations but don’t alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
• Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Trading Down 1.0%

UTHR opened at $564.81 on Friday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $607.89. The company has a market cap of $24.76 billion, a P/E ratio of 20.24, a price-to-earnings-growth ratio of 1.66 and a beta of 0.75. The company has a fifty day moving average price of $504.78 and a two-hundred day moving average price of $477.55.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.19 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.